News + Font Resize -

Pfizer announces top-line results from two phase III trials of tofacitinib in adults with moderate-to-severe chronic plaque psoriasis
New York | Friday, October 11, 2013, 13:00 Hrs  [IST]

Pfizer Inc. has reported top-line results from two phase III clinical trials of tofacitinib, a novel, oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111). These are the first two of five studies in the phase III Oral Psoriasis Treatment (OPT) Programme, one of the largest global clinical trial programmes in moderate-to-severe chronic plaque psoriasis to date.

Top-line results for the OPT Pivotal 1 and OPT Pivotal 2 trials (A3921078 and A3921079) are anticipated in the second quarter of 2014, and these four studies, in addition to a long-term extension study, will form the potential psoriasis submission package to regulatory authorities.

“We are excited to see progress in our development programme in psoriasis,” said Dr Steven Romano, senior vice president and the head of the Medicines Development Group for Pfizer Specialty Care.  “The OPT Compare and OPT Retreatment studies provide information that is consistent with our expectations based on the phase II data in psoriasis. We look forward to the results of our remaining phase III trials in order to fully evaluate tofacitinib in psoriasis and how it may fit into clinical practice for patients and physicians.”

OPT Compare is a 12-week, non-inferiority study comparing the efficacy and safety of tofacitinib 5 and 10 mg twice-daily (BID) to high-dose ENBREL (etanercept) 50 mg twice-weekly (BIW), the approved starting dose for ENBREL for the first twelve weeks, and placebo for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. Top-line results from the OPT Compare study showed that tofacitinib met the primary endpoint of non-inferiority to high-dose ENBREL at the 10 mg BID dose. Tofacitinib did not meet the non-inferiority criteria to high-dose ENBREL at the 5 mg BID dose. The dose-response relationship observed for tofacitinib in this trial is consistent with the findings from the phase II trial. Additionally, rates of important safety events were similar across the active treatment arms.

OPT Retreatment is a 56-week study comparing the efficacy and safety of withdrawal and retreatment with tofacitinib 5 and 10 mg BID to placebo for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis. The OPT Retreatment study met its primary efficacy endpoints at the 5 and 10 mg BID doses by demonstrating that a greater proportion of patients continuing tofacitinib treatment maintained their response during the treatment withdrawal phase compared to patients who switched to placebo.  Additionally, among patients who lost an adequate response, many were able to recapture their response upon retreatment with tofacitinib.  The results of OPT Retreatment will provide relevant information to physicians in clinical practice, as it is common for patients with psoriasis to stop and restart therapy.

No new safety signals for tofacitinib were observed in these studies, and the efficacy and safety profile of tofacitinib in psoriasis remains consistent with that seen in the phase II clinical trial.

OPT Compare was a phase III randomized, double-blind, placebo-controlled 12-week non-inferiority study comparing the efficacy and safety of tofacitinib 5 and 10 mg BID to ENBREL (etanercept) 50 mg BIW and placebo for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who had an inadequate response to, intolerance to, or contraindication to systemic therapy.  There were 1106 patients enrolled in this study. The primary objectives of the study were to compare the efficacy of tofacitinib to ENBREL and placebo for the reduction in severity of plaque psoriasis as measured by the proportion of patients achieving a Physician’s Global Assessment (PGA) response of “clear” or “almost clear,” and the proportion of patients achieving at least a 75 per cent reduction in Psoriasis Area and Severity Index (PASI75) relative to baseline, two commonly used measures of efficacy in psoriasis.

OPT Retreatment was a phase III randomized, mixed-blind, three-period, parallel group, placebo-controlled study evaluating the efficacy and safety of the withdrawal and retreatment with tofacitinib 5 and 10 mg BID to placebo in adult patients with moderate-to-severe chronic plaque psoriasis. There were 674 patients enrolled in the study.  During period A (24 weeks), patients were treated with tofacitinib at a dose of 5 or 10 mg BID in a blinded manner.  To qualify for period B, patients had to achieve both a PASI75 and a PGA response of “clear” or “almost clear”. In period B, patients were randomized to either continue tofacitinib or switch to placebo for 16 weeks or until they lost half of their original PASI response to treatment from Period A, whichever occurred first.  In period C, all patients resumed their original tofacitinib dose until week 56. One of the primary objectives of the study was to compare the maintenance of response (period B, withdrawal) with tofacitinib relative to placebo at various time points during the 16 week double-blind active or placebo treatment period.  The second primary objective of the study, evaluated in period C (retreatment), was to assess the percentage of patients who regained responses with tofacitinib retreatment after having lost adequate responses during period B.  The data announced today are from the planned final analysis at 56 weeks.

The phase III OPT clinical trial programme consists of five studies, including one open-label, long-term extension study evaluating oral tofacitinib 5 and 10 mg BID in adults with moderate-to-severe chronic plaque psoriasis.  It is a global, multi-study, comprehensive clinical development programme that includes 3,600 patients in 39 countries.  The OPT Programme is designed to specifically evaluate tofacitinib in moderate-to-severe chronic plaque psoriasis, and to support an independent assessment of the benefit:risk profile of tofacitinib in psoriasis patients.

Tofacitinib is a novel oral Janus kinase (JAK) inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis.

Discovered and developed by Pfizer scientists, tofacitinib has a novel mechanism of action specifically designed to inhibit the JAK pathways, which are signaling pathways inside the cell that are thought to play a role in the chronic inflammatory responses involved in psoriasis. By inhibiting these JAK pathways, tofacitinib reduces cytokine signaling, cytokine-induced gene expression and activation of cells, which when over activated, results in the immune and inflammatory response, which characterizes psoriasis.

Pfizer strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.

Post Your Comment

 

Enquiry Form